ICU Patients Often Receive Inappropriate Doses of Xarelto, New Study Suggests

Published on January 26, 2015 by Sandy Liebhard

Text-Size:A A A+

 

One out of every three patients given Pradaxa, Eliquis or a medication now involved in several Xarelto lawsuit filings may be receiving inappropriate doses, a new study finds.

According to research presented at a December 2014 meeting of the Society of Critical Care Medicine, a team from Farleigh Dickinson University School of Pharmacy found that a little less than half of individuals treated with the above anticoagulants in intensive care unit (ICU) were given incorrect doses.

Four out of 21 patients were mistreated because doctors did not factor in whether they suffered a bleeding event or were experiencing kidney function problems, the study found. Those with renal impairments were also not treated properly, since the fact that these problems may inhibit the body’s ability to rid the body of blood thinners was not considered. As such, researchers found that patients may be at an increased risk of Pradaxa, Eliquis or Xarelto internal bleeding, which may be uncontrollable since none of these medications have reversal agents to stop episodes once they begin. Dangerous bleeding caused by the decades-old anticoagulant, warfarin can be stopped via the administration of Vitamin K, comparatively.

Most of the patients in the Fairleigh Dickinson study were given Xarelto, Pradaxa and Eliquis for stroke prevention, while others took them as a means of reducing their risk for blood clot problems.

Xarelto Most Common Drug Given to Study Participants

According to the research, Xarelto, was given to nine patients in the study, making it the most commonly-administered among the two others, Eliquis and Boehringer Ingelheim’s Pradaxa.

The findings of this study are noteworthy, given the lawsuits that have already been filed against Xarelto’s manufacturers, Bayer Healthcare and the Johnson and Johnson subsidiary, Janssen Pharmaceuticals. In December 2014, claims that allege serious internal bleeding episodes caused by the blood thinner were centralized in a federal multidistrict litigation underway in the U.S. District Court, Eastern District of Louisiana.

A number of additional Xarelto-related claims have also been centralized in the Philadelphia Court of Common Pleas, where a mass tort program was created on January 20, 2015. According to an Order issued that day, more than 73 product liability lawsuits involving the medication were transferred to Pennsylvania as of January 14th.

Call a Xarelto Lawyer Today

Call a Xarelto lawyer today if you or a loved one sustained a life-threatening episode of internal bleeding after use of the blood thinner. Contact us now at .

Web Analytics